Home » Investors

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Somavaratan is intended to reduce the injection burden of daily therapy and improve therapeutic outcomes through enhanced adherence and convenience with twice-monthly dosing, a fine gauge needle autoinjector device and room temperature storage.

Versartis is currently evaluating somavaratan for the treatment of pediatric GHD in the Phase 3 VELOCITY trial in the U.S., Canada and Europe (data anticipated Q3 2017), and the J14VR5 Phase 2/3 trial in Japan. In adult GHD, Versartis reported results from the Phase 2 VITAL trial and expects to begin a Phase 3 trial by year end 2017.

Presentations, Events and Webcasts

Upcoming events are not available at this time. Sign up for email alerts.

SEC Filings

Financial statements and other formal documents submitted to the U.S. Securities and Exchange Commission